Aclaris Therapeutics Inc (NASDAQ:ACRS) – Investment analysts at Leerink Swann lifted their Q1 2017 earnings per share estimates for shares of Aclaris Therapeutics in a research report issued on Wednesday. Leerink Swann analyst S. Fernandez now forecasts that the brokerage will post earnings per share of ($0.45) for the quarter, up from their previous forecast of ($0.54). Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ Q2 2017 earnings at ($0.60) EPS, Q3 2017 earnings at ($0.81) EPS, Q4 2017 earnings at ($1.08) EPS, FY2017 earnings at ($2.94) EPS and FY2018 earnings at ($3.43) EPS.

ACRS has been the topic of several other research reports. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 2nd. Guggenheim upped their price objective on shares of Aclaris Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 15th. Finally, Jefferies Group LLC set a $36.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Thursday, March 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $36.25.

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Your IP Address:

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Monday. The company’s market capitalization is $618.96 million. Aclaris Therapeutics has a 12 month low of $14.12 and a 12 month high of $33.25. The stock’s 50 day moving average is $28.79 and its 200 day moving average is $26.33.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, March 15th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.10.

Several institutional investors have recently bought and sold shares of the stock. Norges Bank bought a new position in Aclaris Therapeutics during the fourth quarter worth $900,000. EcoR1 Capital LLC bought a new position in Aclaris Therapeutics during the fourth quarter worth $11,236,000. Boothbay Fund Management LLC bought a new position in Aclaris Therapeutics during the fourth quarter worth $264,000. Perceptive Advisors LLC bought a new position in Aclaris Therapeutics during the fourth quarter worth $34,219,000. Finally, Deerfield Management Co. boosted its position in Aclaris Therapeutics by 223.3% in the fourth quarter. Deerfield Management Co. now owns 375,000 shares of the company’s stock worth $10,178,000 after buying an additional 259,000 shares in the last quarter. Hedge funds and other institutional investors own 61.94% of the company’s stock.

In other news, Director Anand Mehra sold 750,000 shares of the company’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $28.25, for a total value of $21,187,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of the company’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total transaction of $13,098,500.00. The disclosure for this sale can be found here. 46.40% of the stock is owned by corporate insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

5 Day Chart for NASDAQ:ACRS

Receive News & Stock Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related stocks with our FREE daily email newsletter.